Fibre boosting GLP-1 hormone approved for EU foods

A modified fibre known as inulin-propionate ester has received safety approval from the European Food Safety Authority, paving the way for its addition to everyday products such as breads and cereals.

The fibre, called IPE, was developed by researchers Gary Frost at Imperial College London and Douglas Morrison at the University of Glasgow. It works by releasing propionate in the large intestine, which raises levels of hormones including GLP-1 and PYY that help control appetite.

Trials showed that a daily 10-gram dose prevented weight gain in people aged 40 to 65 and increased fat-free mass in those aged 20 to 40. The only noted side effect was increased flatulence.

It took 12 years to secure the EU approval. The developers expect products containing IPE to reach the market within the next 12 months. A researcher at the University of Aberdeen noted that the trial evidence for weight benefits remains limited in scale.

Labaran da ke da alaƙa

Medical team discussing integrated obesity care with GLP-1 drugs, endoscopy, surgery and precision medicine.
Hoton da AI ya samar

Updated POWER framework urges multidisciplinary obesity care beyond GLP-1 drugs

An Ruwaito ta hanyar AI Hoton da AI ya samar An Binciki Gaskiya

A new Gastroenterology commentary revisits the American Gastroenterological Association’s 2017 POWER framework, arguing that GLP-1 medicines should be integrated with endoscopic therapies, bariatric surgery and precision medicine to improve long-term obesity outcomes.

Scientists have developed a hybrid obesity treatment that uses GLP-1 and GIP signals to deliver a metabolic enhancer directly into cells. Early tests in mice showed greater weight loss and better blood sugar control than standard therapies. The approach aims to reduce side effects by limiting the drug's action to targeted areas.

An Ruwaito ta hanyar AI

A new experimental oral medication called elecoglipron improved blood sugar control and promoted weight loss in adults with type 2 diabetes during a phase 2b trial. Results from the SOLSTICE study were presented at the American Diabetes Association's Scientific Sessions and published in The Lancet.

Eliminating sucrose from a low-fat diet worsened glucose tolerance and altered the gut microbiome in mice over 16 weeks, according to results presented on Saturday, June 13, 2026, at ENDO 2026, the Endocrine Society’s annual meeting in Chicago.

An Ruwaito ta hanyar AI An Binciki Gaskiya

Adults with obesity who began taking GLP-1 receptor agonist medications showed declines in Fitbit-measured physical activity after starting treatment, according to a retrospective study presented Saturday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago.

Wannan shafin yana amfani da cookies

Muna amfani da cookies don nazari don inganta shafin mu. Karanta manufar sirri mu don ƙarin bayani.
Ƙi